Clinical Trial

Single-Fraction SBRT Versus Standard Palliative Radiation Therapy in Treating Patients With Metastatic Cancer

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This phase II trial studies how well single-fraction stereotactic body radiation therapy (SBRT) works when compared to standard radiation therapy in treating patients with cancer that has spread to other places in the body (metastatic). Stereotactic body radiation therapy uses special equipment to position a patient and deliver radiation to tumors with high precision. This method can kill tumor cells with fewer doses over a shorter period and cause less damage to normal tissue.
Protocol Amendment History 13 amendments
This ClinicalTrials.gov record has been amended 13 times since 2019-08-22; most recent amendment 2026-04-24.
Status change: Not Yet Recruiting → Recruiting 2019-11-18
Trial Details
NCT Number NCT04068649
Lead Sponsor Roswell Park Cancer Institute
Conditions Metastatic Malignant Neoplasm
Enrollment 1,500 participants
Start Date 2019-11-18
Primary Completion 2027-11-18 (estimated)
Study Completion 2027-11-18 (estimated)
Updated on ClinicalTrials.gov 2026-04-30